Sortilin、氨甲酰化和慢性肾脏病中的心血管钙化。
Sortilin, carbamylation, and cardiovascular calcification in chronic kidney disease.
机构信息
Department of Nephrology, Ambroise Paré University Medical Center, Assistance Publique - Hôpitaux de Paris, Boulogne-Billancourt/Paris, France; Inserm 1018 Team5, Université Paris-Saclay, Université Versailles Saint-Quentin-en-Yvelines, Inserm, Clinical Epidemiology Team, Centre de Recherche en Epidémiologie et Santé des Populations, Villejuif, France.
Pharmacology Department, Amiens University Medical Center, Amiens, France; Research Unit, MP3CV Laboratory, EA7517, University of Picardie Jules Verne, Amiens, France.
出版信息
Kidney Int. 2022 Mar;101(3):456-459. doi: 10.1016/j.kint.2021.11.027.
Sortilin appears to play important roles in the pathogenesis of vascular and metabolic diseases, such as cardiovascular calcification. Post-translational modifications of sortilin (i.e., phosphorylation or carbamylation) are among the key mechanisms of its actions. Recent data extended the role of carbamylated sortilin to the pathogenesis of cardiovascular calcifications in chronic kidney disease. Whether therapeutic tools potentially available to inhibit the carbamylation process in chronic kidney disease patients would allow preventing cardiovascular calcifications remains to be demonstrated.
Sortilin 似乎在血管和代谢疾病（如心血管钙化）的发病机制中发挥重要作用。Sortilin 的翻译后修饰（如磷酸化或氨甲酰化）是其作用的关键机制之一。最近的数据将氨甲酰化 sortilin 的作用扩展到慢性肾脏病中心血管钙化的发病机制中。在慢性肾脏病患者中，是否有潜在的治疗工具可以抑制氨甲酰化过程，从而防止心血管钙化，仍有待证实。
Zotero 插件